Overview
Kynexis is a biotechnology company specializing in biomarker-guided therapeutic development for neuropsychiatric and cognitive impairment disorders. The company employs a biomarker-based approach to optimize pharmacokinetics and enable targeted therapy design in clinical trials for neuropsychiatric drugs.
More in Neurotechnology
Latest industry news
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Tether Evo Takes On One of BCI's Hardest Engineering Problems
2026-09-19 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →